Marketing researchers spread thin, data show

Data indicate a noticeable step-up in the workload for market research pros based at pharmaceutical firms.
The primary research spend managed per full-time employee (FTE) increased significantly over the last five years from roughly $849,000 in 2006 to nearly $1.4 million in 2010, figures from TGaS Advisors show. Data were presented at the Pharmaceutical Marketing Research Group Annual National Conference in March.
TGaS does not have a generally accepted opinion about the right workload. Heavier workloads were more a factor of manufacturers thinning out their ranks than shrinking MR budgets. “Brand managers' demand for research hasn't really changed—the same issues have to be tracked,” explained TGaS's John Kain, VP, management advisor. “Our hypothesis is that budgets are tightened and headcount is shrunk or allowed to attrition accordingly—and then brand teams come up with funds for necessary research.”
TGaS derives the metric by dividing the total external market research spend per year by the number of FTEs managing those research projects. Calculations were derived from 8-11 benchmarks per year, Kain said.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.